Enanta Pharmaceuticals
ENTA
#7715
Rank
NZ$0.39 B
Marketcap
$18.54
Share price
-2.47%
Change (1 day)
24.53%
Change (1 year)

P/E ratio for Enanta Pharmaceuticals (ENTA)

P/E ratio as of November 2024 (TTM): -1.77

According to Enanta Pharmaceuticals 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -1.76545. At the end of 2022 the company had a P/E ratio of -7.99.

P/E ratio history for Enanta Pharmaceuticals from 2013 to 2023

PE ratio at the end of each year

Year P/E ratio Change
2022-7.99-46.77%
2021-15.02.72%
2020-14.6-140.7%
201935.9125.66%
201815.9-51.18%
201732.6-148.66%
2016-67.0-781.77%
20159.83-14.77%
201411.5-229.34%
2013-8.92

P/E ratio for similar companies or competitors

Company P/E ratio P/E ratio differencediff. Country
54.6-3,191.41%๐Ÿ‡บ๐Ÿ‡ธ USA
11.1-727.50%๐Ÿ‡บ๐Ÿ‡ธ USA
39.6-2,345.87%๐Ÿ‡บ๐Ÿ‡ธ USA
56.6-3,306.38%๐Ÿ‡บ๐Ÿ‡ธ USA
13.7-874.09%๐Ÿ‡บ๐Ÿ‡ธ USA
28.4-1,711.14%๐Ÿ‡จ๐Ÿ‡ญ Switzerland

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.